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CYP2C19*2 and CYP2C19*17 
variants and effect of tamoxifen on 
breast cancer recurrence: Analysis 
of the International Tamoxifen 
Pharmacogenomics Consortium 
dataset
Per Damkier  1,2, Anders Kjærsgaard  3, Kimberly A. Barker4, Deidre Cronin-Fenton3, 
Anatasha Crawford5, Ylva Hellberg6, Emilius A. M. Janssen7, Carl Langefeld8, Thomas P. 
Ahern9 & Timothy L. Lash3,5
The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of 
breast cancer is subject to substantial interest and controversy. CYP2D6 have been intensively studied, 
but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and 
recurrence of breast cancer. We used outcome and genotyping data from the large publicly available 
International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset. Cox regression was used 
to compute the hazard ratios (HRs) for recurrence. CYP2C19 genotype data was available for 2 423 
patients and the final sample cohort comprised 2 102 patients. CYP2C19*2 or *19 alleles did not 
influence DFS. For the CYP2C19*2 allele, the HR was 1.05 (CI 0.78–1.42) and 0.79 (CI 0.32–1.94) for 
hetero- and homozygote carriers, respectively. The corresponding HR for hetero- and homozygote 
carriers of the CYP2C19*17 allele were 1.02 (CI 0.71–1.46) and 0.57 (CI 0.26–1.24), respectively. 
Accounting for CYP2D6 genotype status did not change these estimates. We found no evidence to 
support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast 
cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical 
decisions on tamoxifen treatment.
Breast cancer is, excluding skin cancers, the most common malignancy among women in the United States and 
caused about 571.000 deaths world-wide in 20151, 2. Tamoxifen is the standard treatment for premenopausal 
women with estrogen receptor (ER) positive breast cancer, and five years of adjuvant tamoxifen therapy reduces 
recurrences by nearly 50%3–5. In tumor cells, tamoxifen and its metabolites impede the binding of estrogen to the 
ER to inhibit expression of estrogen-responsive genes, thereby preventing tumor cell growth and angiogenesis6, 7. 
Patient responses to tamoxifen vary, and around 20–30% of patients receiving tamoxifen therapy in accordance 
with guidelines still suffer a breast cancer recurrence8.
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The complex tamoxifen metabolism (Fig. 1) is primarily catalyzed by cytochrome P450 (CYP) enzymes, 
which are subject to substantial differences in inter-individual expression and activity9–12. Endoxifen, the 
4-hydroxy-N-desmethyl metabolite of tamoxifen, is central to mechanism of action and efficacy of tamoxifen, and 
concentrations thereof varies substantially between patients6, 13, 14. CYP2D6 is the principal enzyme catalyzing the 
conversion of tamoxifen to endoxifen, and the association of genomic variants in the CYP2D6 gene to outcome 
of tamoxifen treatment has been extensively studied15, 16. Two of the largest datasets reported a null-association, 
but contradictory findings have led to ongoing controversy over the value of using CYP2D6 genotyping to guide 
the prescription of tamoxifen17–22.
CYP2C19 catalyzes the formation of a proportion of tamoxifen metabolites, including the conversion of 
4-OH-TAM to endoxifen (Fig. 1)23. The CYP2C19 gene is highly polymorphic. Loss of enzyme activity results 
from the CYP2C19*2 (681 G > A, rs4244285)24, 25 and CYP2C19*3 (636 G > A, rs4986893) alleles26, 27. The *2 
allele is found in approximately 23–39% of Asians, 10–20% of Caucasians, and 15% of Africans23, 28. The *3 allele 
occurs in 5–10% of Asians (17). CYP2C19*17 (−806C > T, rs12248560 or −3402C > T, rs11188072) has been 
implicated in enhanced gene transcription26, 29, 30. The *17 allele is found in about 4% of Asians and 18–24% of 
Caucasians and Africans23, 28, 31, 32.
Studies differ with respect to the associations observed between CYP2C19 genotypes and clinical outcomes as 
well as to corresponding levels of tamoxifen and its metabolites33–38. Counterintuitively, the presence of a *2 allele 
has been associated with longer relapse-free time or better survival in tamoxifen-treated women in some39–41, but 
not all studies32, 42–46. In some studies the CYP2C19*17 allele is associated with more favorable outcomes in breast 
cancer patients treated with tamoxifen32, though null results have also been found40, 42, 43, 47. Contradictory results 
were obtained in the context of tamoxifen monotherapy in advanced breast cancer, where an association between 
the *17 allele and shorter time to treatment failure has been reported39, 41.
Given these contradictory findings, we used a large, publicly available dataset to investigate the association of 
CYP2C19*2 and CYP2C19*17 variants with breast cancer recurrence in both pre- and postmenopausal women 
treated with adjuvant tamoxifen therapy for ER-positive breast cancer.
Subjects and Methods
Data source and study population. The ITPC comprises research from 12 sites representing 9 countries, 
all designed to prospectively assess the contribution of genetic variation in tamoxifen metabolism and transport 
pathways to breast cancer recurrence risk. We required that patients had been prescribed 20 mg/day tamox-
ifen for an intended duration of 2 or 5 years, had not previously received systemic therapy for breast cancer 
prevention, had no known history of invasive or in situ breast cancer, had not used any other adjuvant therapy 
before tamoxifen, and initiated tamoxifen therapy within 182 days of breast cancer surgery. We included patients 
with non-metastatic, ER-positive tumors who had data on at least one CYP2C19 variant, whether a recurrence 
occurred, and follow-up time (Fig. 2).
Analytic variables. Disease-free survival time (DFS) was the number of months from diagnosis until breast 
cancer recurrence, defined as an ipsilateral local or regional recurrence (invasive or non-invasive), a distant recur-
rence, or a contralateral breast cancer (invasive or non-invasive). Patients who did not experience a recurrence 
were censored on the date of death from another cause or on the day of last disease-free evaluation.
Genotype exposures were CYP2C19*2 and CYP2C19*17, with reference to the wild-type CYP2C19*1. Various 
methods of genotyping were used in the seven studies comprising the data, with the majority of genotypes 
(60.5%) ascertained by the AmpliChip test platform (Roche Molecular Diagnostics, California, USA). In three 
Figure 1. The metabolism of tamoxifen.
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instances where multiple methods were used for a single individual and the AmpliChip blood genotype did not 
match the CYP2C19*2 genotype obtained with another method, preference was given to the AmpliChip data due 
to the high sensitivity and specificity of this test49. The CYP2C19*3 allele was not assessed in this study because no 
variants were detected in the included data.
Covariables. Potential covariates of interest were: age, ethnicity, menopausal status, tumor grade and 
stage, progesterone receptor (PR) status, use of other adjuvant therapies (radiation and chemotherapy), and 
CYP2D6 metabolizer phenotype. Age (as a continuous variable), menopausal status (pre-, post-, or peri-), PR 
status, use of other adjuvant therapies, and Nottingham tumor grades were recorded directly in the ITPC data-
set. Perimenopausal women (n = 57) were combined with post-menopausal women for all analyses. Categories 
as defined by the Office of Management and Budget50 were used to divide patients into three ethnic groups: 
Caucasian, Asian or Pacific Islander, and any other ethnicity (which included African-Americans, mixed ethnic-
ity individuals, and individuals of any other ethnicity).
Tumor stage was derived from information on both tumor diameter and the number of positive lymph nodes. 
Missing information on in situ tumors and distant metastases prohibited use of the TNM staging system; however, 
the primary tumor and pathologic guidelines of the TNM system were used to classify tumors into five stages51.
A variable encoding individuals’ CYP2D6 metabolizer phenotype (ultra- UM, extensive- EM, intermediate- 
IM, or poor- PM) was available in the ITPC data, and accounted for both genetic factors and the use of 
CYP2D6-inhibiting drugs. We generated a variable designating overall tamoxifen metabolic activity (high, inter-
mediate or low) by combining CYP2D6 phenotypes and CYP2C19 genotypes according to Schroth (Table 1)32.
Statistical analyses. Descriptive analyses including all covariates of interest were computed for all women 
analyzed. Cox regression was used to compute the hazard ratios (HRs) for recurrence and associated 95% con-
fidence intervals (CIs). The tumor grade variable violated the proportional hazards assumption when assessed 
using log-log survival curves and were therefore excluded from all models. Models containing all possible varia-
ble subsets were analyzed using the change-in-estimate approach, with confounding indicated in models where 
the variable subset removed led to a hazard ratio changed by greater than 10% compared with the hazard ratio 
for the full model52. Final Cox proportional hazards models included age at diagnosis of primary breast cancer 
(as a continuous variable), tumor stage, and ethnicity (Caucasian or Asian, for CYP2C19*2 only) as covariates. 
Supplemental analyses stratified by CYP2D6 phenotype and menopausal status were also performed.
For multivariable analyses, individuals with missing values for any modeled variable were excluded. To assess 
the potential for bias due to the use of complete case analyses, imputation of missing values for CYP2C19*2 
genotype, CYP2C19*17 genotype, ethnicity, age at breast cancer diagnosis, and tumor stage was done in a sup-
plemental analysis.
All analyses were carried out in SAS version 9.4 (Cary, NC).
Data availability statement. Data were obtained from the International Tamoxifen Pharmacogenomics 
Consortium (ITPC) which are publicly available48.
Results
Study population. The seven sites containing eligible patients provided 2 102 women for analysis (Fig. 2). 
Of these, 296 women experienced a breast cancer recurrence. One woman who did not have a recurrence and was 
missing data on the last disease-free evaluation was censored on the date she was last known to be alive. Patient 
characteristics for the sample and source population by study site are presented in Table 2 and Supplementary 
Table S1, respectively. Characteristics of the sample and source data stratified by recurrence are presented in 
Supplementary Table S2. The median DFS was 61 months for all women, 45 months for women experiencing a 
recurrence, and 63 months for women with no recurrence.
Figure 2. Study population flowchart.
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Genotypes. Data on CYP2C19*2 were available from all seven study sites for 2 055 women, and data on 
CYP2C19*17 were reported from three sites for 1 253 women. Distributions and Hardy-Weinberg chi-squared 
statistics within each study site for the CYP2C19*2 and CYP2C19*17 genotypes and DNA sources are provided 
for sample and source populations in Supplementary Tables S3 and S4. Both variants were in Hardy-Weinberg 
equilibrium for each study site, except for CYP2C19*17 at site 8 (p = 0.02) and CYP2D6*2 at site 12 (p = 0.005)
CYP2C19 genotypes and DFS. For the CYP2C19*2 allele, adjusted hazard ratios for associations between 
variant heterozygotes and homozygotes with DFS were 1.05 (95% CI: 0.78, 1.42) and 0.79 (95% CI: 0.32, 1.94), 
respectively (Table 3). For the CYP2C19*17 allele, adjusted hazard ratios for associations between variant hete-
rozygotes and homozygotes with DFS were 1.02 (95% CI: 0.71, 1.46) and 0.57 (0.26, 1.24), respectively (Table 3). 
Stratification by menopausal status and CYP2D6 phenotype did not yield any notable associations between 
CYP2C19 genotype and DFS (Supplementary Table S5). Results based on imputed data sets were not substantially 
different from the complete case analysis, but in general tended to be closer to the null (Supplementary Table S6).
CYP2D6 phenotype/CYP2C19 genotype combinations. Results are provided in Table 4. For the 
CYP2D6 phenotype/CYP2C19*2 genotype combinations, multivariate DFS hazard ratios for the phenotypically 
designated “high” and “intermediate” tamoxifen metabolic activity groups were 0.86 (95% CI: 0.45–1.66) and 
0.89 (95% CI: 0.46–1.74), respectively, compared with the “low” metabolic activity group. The corresponding 
adjusted DFS hazard ratios for the CYP2D6 phenotype/CYP2C19*17 genotype combinations were 1.19 (95% CI: 
0.73–1.94) and 1.21 (95% CI: 0.80–1.85).
Discussion
We found no evidence of a clinically meaningful association between CYP2C19*2 or CYP2C19*17 genotypes and 
DFS in tamoxifen-treated breast cancer patients in a large dataset. A secondary analysis of CYP2C19 genotype 
accounting for CYP2D6 phenotypes resulted in little change to the observation.
This study has the largest overall sample size of work on this topic to date and includes a larger number of 
CYP2C19 variants compared with prior studies. Even so, our estimates come with confidence intervals that sug-
gest some limitation with respect to sample-size This study also benefits from the inclusion of a substantial num-
ber of premenopausal patients, permitting stratification of the association by menopausal status. Only two other 
studies have examined the association between CYP2C19 genotype and breast cancer recurrence within strata 
of menopausal status42, 44, and those studies included a combined total of only 85 premenopausal patients. The 
inclusion of a large premenopausal cohort is especially relevant as tamoxifen is the guideline endocrine therapy 
for these women5.
Combining CYP2D6 and CYP2C19*2 or CYP2C19*17 into singular phenotypes (as suggested by Schroth 
et al.32) did not suggest that this is of clinical relevance (Table 4). While this finding should be interpreted with 
caution, as confidence intervals are somewhat wide, this analysis indirectly lends further weight against the heav-
ily discussed clinically meaningful role of CYP2D6 itself. Our results differ somewhat from those reported by 
Inferred phenotype levels of combined CYP2D6 phenotypes1 and CYP2C19*17 genotypes
Level CYP2D6 phenotype CYP2C19*17 allele presence
1 EM/EM Yes
2
EM/EM No
EM/IM Yes
EM/PM Yes
3
EM/IM No
EM/PM No
IM/PM Yes or No
IM/IM Yes or No
PM/PM Yes or No
Inferred phenotype levels of combined CYP2D6 phenotypes1 and CYP2C19*2 genotypes
Level CYP2D6 phenotype CYP2C19*2 allele presence
1 EM/EM No
2
EM/EM Yes
EM/IM No
EM/PM No
3
EM/IM Yes
EM/PM Yes
IM/PM Yes or No
IM/IM Yes or No
PM/PM Yes or No
Table 1. Phenotype assignment according to CYP2D6 and CYP2C19 genotype. 1CYP2D6 UM considered as 
EM for creation of these levels.
www.nature.com/scientificreports/
5SCIENTIFIC RepoRts | 7: 7727  | DOI:10.1038/s41598-017-08091-x
Schroth, who reported a statistically significant inference of the CYP2C19*17 allele on event-free survival32. Our 
sample size is several orders of magnitude larger though, which we believe explains this apparent discrepancy.
Total N
Project site
Total2 4 6 8 9 11 12
186 217 191 875 73 305 255 2102
Median DFS in months (range)
Median 45 52 124 64 28 65 68 61
Min 7.2 1.2 3.1 2.1 7.1 0.33 4.2 0.33
Max 173 81 207 244 132 140 121 244
Age at diagnosis
Mean 54 51 61 65 48 62 45 59
SD 11 10 10 9.8 10 14 8 13
Recurrence
No
N 141 214 123 756 71 262 239 1806
% 75.8 98.6 64.4 86.4 97.3 85.9 93.7 85.9
Yes
N 45 3 68 119 2 43 16 296
% 24.2 1.4 35.6 13.6 2.7 14.1 6.3 14.1
Menopausal status at diagnosis
Missing
N 4 4 40 0 0 20 208 276
% 2.2 1.8 20.9 0 0 6.6 81.6 13.1
Premenopausal
N 78 64 10 43 0 66 0 261
% 41.9 29.5 5.2 4.9 0 21.6 0 12.4
Postmenopausal
N 104 149 141 832 73 219 47 1565
% 55.9 68.7 73.8 95.1 100 71.8 18.4 74.5
CYP2C19*2 genotype
Missing or unknown
N 3 1 0 43 0 0 0 47
% 1.6 0.5 0 4.9 0 0 0 2.2
Wild type
N 124 151 140 586 51 226 139 1417
% 66.7 69.6 73.3 67 69.9 74.1 54.5 67.4
One null function allele
N 57 61 48 223 17 75 86 567
% 30.6 28.1 25.1 25.5 23.3 24.6 33.7 27
Two null function alleles
N 2 4 3 23 5 4 30 71
% 1.1 1.8 1.6 2.6 6.8 1.3 11.8 3.4
CYP2C19*17 genotype
Missing or unknown
N 0 0 191 25 73 305 255 849
% 0 0 100 2.9 100 100 100 40.4
Wild type
N 107 133 0 489 0 0 0 729
% 57.5 61.3 0 55.9 0 0 0 34.7
One gain of function allele
N 73 78 0 294 0 0 0 445
% 39.2 35.9 0 33.6 0 0 0 21.2
Two gain of function alleles
N 6 6 0 67 0 0 0 79
% 3.2 2.8 0 7.7 0 0 0 3.8
Table 2. Sample population characteristics.
Comparison Hazard Ratio (95% CI); (N)
CYP2C19*2
Genotypes
No *2 allele 1.0 (Reference); (971)
*2/*1 1.05 (0.78–1.42); (420)
*2/*2 0.79 (0.32–1.94); (54)
CYP2C19*17
Genotypes
No *17 allele 1.0 (Reference); (609)
*17/*1 1.02 (0.71–1.46); (361)
*17/*17 0.57 (0.26–1.24); (71)
Table 3. Cox proportional hazard ratios for CYP2C19*2 and CYP2C19*17 genotypes and Disease Free 
Survival.
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At ITPC sites not testing for the CYP2C19*17 allele, misclassification of tamoxifen metabolic phenotype could 
have occurred, but a stratified sensitivity analysis restricted to sites testing for CYP2C19*17 did not provide 
substantially different results. CYP2C19*3 allele misclassification is unlikely to influence the overall result as this 
allele would only be expected to be common at site 1223. Allele distribution was reasonably consistent across study 
sites and compared well to reported literature frequencies. This suggest that errors from genotyping are less likely 
to present a main issue within our dataset. The CYP2C19*2 allele was assessed across 10 study sites. The allele 
frequencies were reasonably comparable, 23–31% for heterozygosity, bar two sites (project site #6 and #12) which 
yielded frequencies of 18 and 35% for *2 heterozygosity, respectively. These frequencies are within reason of the 
expected given the variability related to sample size and ethnicity composition of the respective populations. Site 
12 had a relative low sample size and site 6 a high degree of missing values (32%). The latter diluted the frequency 
as, among those tested, 26% were heterozygous for the *2 allele. The CYP2C19*17 was only assessed at three sites 
that yielded homogenous and comparable allele frequencies with one gain of function allele frequencies between 
32–37%. Allele distributions per ethnicity (Supplementary Table S5) compared well to reported literature fre-
quencies, though we could not meaningfully compare the *17 allele frequency in Asian subjects to literature 
data as very few of Asian origin were tested in our sample. The lack of data on CYP2C19 inhibitor use could 
have biased our estimates towards the null. CYP2C19 genotyping using tumor-derived DNA (at three sites) may 
introduce misclassification due to potential loss-of-heterozygosity in tumor cells53, 54.Results of chi-squared tests 
for Hardy-Weinberg equilibrium indicate that loss-of-heterozygosity had a minor impact on observed CYP2C19 
genotypes in this study. A minor violation of HWE was observed at study site 8, which accounted for the majority 
of samples assessed for CYP2C19*17. This minor violation represents a weakness even if misclassification due to 
loss-of-heterozygosity appears less likely to result in significant bias of overall study estimates20. A violation of 
HWE for CYP2C19*2 was observed at study site 12, but the sample of 240 subjects contributed little to the overall 
analysis.
While previous reports have found the presence of CYP2C19*2 to be associated with superior efficacy of 
tamoxifen treatment39–41, our results support other studies reporting no such association32, 42–46. The hazard ratio 
for the association of CYP2C19*17 homozygotes with a favorable DFS (HR = 0.57, 95% CI: 0.26, 1.24) is similar 
to the ratio found previously for the association of carrying CYP2C19*17 with relapse-free time (HR = 0.45, 
95% CI: 0.21, 0.92) (31). About 40% of the patient population and the majority of *17 allele data in the ITPC 
dataset were from the latter study, so our study should not be viewed as independent evidence. Our findings for 
the *17 allele are consistent with results from a smaller, similar study, which reported a hazard ratio of 0.93 (95% 
CI = 0.64, 1.37) and found a near-null association among those with impaired CYP2D647. Despite the biologic 
plausibility of CYP2C19 playing an important role in patients with reduced CYP2D6 function, our stratified 
analyses do not support this hypothesis. The complex metabolism of tamoxifen, which include catalytic activity 
of CYP2C19, CYP1A2, CYP3A4/5, CYP2D6, CYP2B6 and CYP2C9, may explain the null-association found in 
this study. The formation of active tamoxifen metabolites in patients carrying reduced or increased CYP2C19 
function alleles may be sufficiently compensated through parallel and serial metabolic pathways catalyzed by 
other P450 enzymes. This would mitigate the net overall clinical consequence of genomic CYP2C19 variants and 
result in a statistical inference toward the null.
A key limitation is that the ITPC dataset does not allow for differentiation between predictive and prognostic 
markers, since studies did not include women diagnosed with ER-negative tumors who were not treated with 
tamoxifen. Several studies indicate that CYP2C19 variants are associated with differences in baseline breast cancer 
risk, likely due to the inherent role of CYP2C19 in the metabolism of estrogen. However, this association has not 
been consistently observed, and the fact that the minor allele frequencies observed here match population-wide 
benchmarks argues against CYP2C19 genotype as a selection force. On the other hand, breast cancer etiology 
or survival is usually only relevant after childbirth in most women, which would render selection pressure less 
relevant.
Province et al. analyzed the ITPC dataset and reported poorer disease-free survival among CYP2D6 poor 
metabolizers and a weak association between poor metabolizer status and a shorter breast cancer-free interval15. 
These associations were not robust to variations in inclusion criteria, and this study has been heavily criticized 
for its reliance on statistical interpretations of ad hoc subset analyses and this issue remains highly controver-
sial55–58. In light of these criticisms, the criteria for inclusion in our study were defined a priori. Province et al. also 
described the heterogeneity of results between the study sites, which is an additional challenge in interpreting the 
results of our study15.
Comparison Hazard Ratio (95% CI); (N)
CYP2C19*2
Level1 3 1.0 (Reference); (85)
Level 2 0.89 (0.46–1.74); (539)
Level 1 0.86 (0.45–1.66); (836)
CYP2C19*17
Level 3 1.0 (Reference); (230)
Level 2 1.21 (0.80–1.85); (1158)
Level 1 1.19 (0.73–1.94); (376)
Table 4. Cox proportional hazard ratios for combinations of CYP2D6 metabolizer phenotypes with 
CYP2C19*2 or CYP2C19*17 genotypes and Disease Free Survival. 1Levels are defined in Table 1.
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In conclusion, we found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms 
and response to tamoxifen in breast cancer patients. Given the complexity of tamoxifen pharmacodynamics and 
metabolism and the divergent results on the importance of genomic variants, it appears unlikely that a clinically 
useful simple predictive set of genomic variables will be identified.
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